Showing 1 - 10 of 24
"We seek to investigate whether managed health care can affect mortality, and if so, through which mechanisms. We estimate the impact of Medicare+Choice (M+C), Medicare's managed care program, on elderly mortality, using a county-level panel from 1993 to 2000. We control for endogenous M+C...
Persistent link: https://www.econbiz.de/10001903511
Persistent link: https://www.econbiz.de/10009558741
Persistent link: https://www.econbiz.de/10010530694
The standard Medicare Part D drug insurance contract is nonlinear--with reduced subsidies in a coverage gap--resulting in a dynamic purchase problem. We consider enrollees who arrived near the gap early in the year and show that they should expect to enter the gap with high probability, implying...
Persistent link: https://www.econbiz.de/10012457562
Persistent link: https://www.econbiz.de/10012197702
We seek to investigate whether managed health care can affect mortality, and if so, through which mechanisms. We estimate the impact of Medicare+Choice (M+C), Medicare's managed care program, on elderly mortality, using a county-level panel from 1993 to 2000. We control for endogenous M+C...
Persistent link: https://www.econbiz.de/10013313795
The standard Medicare Part D drug insurance contract is nonlinear—with reduced subsidies in a coverage gap—resulting in a dynamic purchase problem. We consider enrollees who arrived near the gap early in the year and show that they should expect to enter the gap with high probability,...
Persistent link: https://www.econbiz.de/10013024154
Persistent link: https://www.econbiz.de/10003972458
We empirically analyze the welfare effects of cross-firm bundling in the pharmaceutical industry. Physicians often treat patients with "cocktail" regimens that combine two or more drugs. Firms cannot price discriminate because each drug is produced by a different firm and a physician creates the...
Persistent link: https://www.econbiz.de/10013138761
The average price of treating a colorectal cancer patient with chemotherapy increased from about $100 in 1993 to $36,000 in 2005, due largely to the approval and widespread use of five new drugs between 1996 and 2004. We examine whether the substantial increase in spending has been worth it....
Persistent link: https://www.econbiz.de/10013152096